Summarized by Masters of Longevity from Nature - Main.
A phase III trial found intismeran with pembrolizumab reduced melanoma recurrence or death by 42%.

Key Takeaways
- The trial enrolled 1,137 people with stage IIIB–IV melanoma.
- Individual vaccines were designed by sequencing each patient's tumour.
- The overall survival outcomes remain uncertain pending longer follow-up.



